Newsfeeds - Spark Newswire

1 minute read

Protagonist Therapeutics Touts Positive Data From Bone Marrow Disorder Study

Today, 10:05 AM

Protagonist Therapeutics Inc (NASDAQ:PTGX) announced topline results from the blinded, placebo-controlled, randomized withdrawal portion of REVIVE of rusfertide for polycythemia vera,…

JNJ

2 minute read

Top 5 Health Care Stocks That Are Ticking Portfolio Bombs

By Lisa Levin

Today, 10:05 AM

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

AMYT

1 minute read

HC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Lowers Price Target to $33

By Benzinga Newsdesk

Today, 10:05 AM

HC Wainwright & Co. analyst Douglas Tsao maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and lowers the price target from $50 to $33.

PTGX

1 minute read

Protagonist Therapeutics Q3 EPS $(0.64) Up From $(0.70) YoY

By Benzinga Newsdesk

Today, 10:05 AM

Protagonist Therapeutics (NASDAQ:PTGX) reported quarterly losses of $(0.64) per share. This is a 8.57 percent increase over losses of $(0.70) per share from the same period last year.

PTGX

2 minute read

Earnings

Protagonist Therapeutics Earnings Perspective: Return On Capital Employed

By Benzinga Insights

Today, 10:05 AM

Protagonist Therapeutics (NASDAQ:PTGX) brought in sales totaling $859 thousand during Q2 according to data provided by Benzinga Pro. However, earnings decreased 96.07%, resulting in a loss of $41.04 million.

PTGX

3 minute read

The Daily Biotech Pulse: INmune Bio’s Planned Alzheimer’s Trial On FDA Hold, Caladrius Stops Enrollment In Heart Disease Study, BiomX Restructures

By Vandana Singh

Today, 10:05 AM

Here's a roundup of top developments in the biotech space over the last 24 hours:

ABBV

2 minute read

The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More

By Shanthi Rexaline

Today, 10:05 AM

Biotech stocks advanced in the week ending May 22, defying the broader market retreat. The defensive nature of the industry and stock-specific moves lent support.

ABBV